Major Biopharm Company Plans Massive Expansion - Credits Big, Beautiful Bill

https://redstate.com/wardclark/2025/09/03/major-biopharm-company-plans-massive-expansion-credits-big-beautiful-bill-n2193524#google_vignette

By Ward Clark  | 11:06 AM on September 03, 2025 

The opinions expressed by contributors are their own and do not necessarily represent the views of RedState.com.

    

AP Photo/Mark J. Terrill, File

Amgen (NASDAQ: AMGN) is a major player in biotech and biopharmaceuticals. They're in the top 20 of biomedical companies by revenue, with over $33 billion in revenue in 2024. Despite California's increasingly hostile work environment, Amgen maintains its primary operation at its Thousand Oaks, California headquarters. Amgen isn't shy about spreading some money around on politics, supporting mostly Democratic candidates and organizations, including Kamala Harris's presidential bid.

Now, though, in a move that's sure to give California's impeccably coiffed Governor Gavin Newsom a headache, Amgen is planning a major expansion of research facilities at their Thousand Oaks headquarters, and in its press release announcing the move, Amgen is giving the Tax Cuts and Jobs Act and the One Big Beautiful Bill (and indirectly, President Trump) credit for making the expansion practical. (Emphasis added by author)

Amgen (NASDAQ: AMGN) today announced plans to invest more than $600 million in a new, state-of-the-art center for science and innovation at its global headquarters in Thousand Oaks, California.

The center is designed to bring together researchers, engineers and scientists across disciplines to enhance collaboration and accelerate the discovery of next-generation therapeutics for patients with the most serious diseases. The building will feature advanced automation and digital capabilities, empowering scientists with the tools and environment needed to drive scientific excellence and advancements in biotechnology.

Amgen's long-standing commitment to U.S. innovation and state-of-the-art operations is reflected in more than $40 billion invested in manufacturing and research and development since the passage of the Tax Cuts and Jobs Act (TCJA) of 2017. This investment includes over $5 billion in direct capital expenditures in the U.S. The enactment of pro-growth tax policies in TCJA, extended and reinforced by the One Big Beautiful Bill Act of 2025, further facilitates Amgen's ability to invest domestically in cutting-edge science and manufacturing.